StemCell Therapy

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President & Chief Executive Officer, and Dave Knop, PhD, Vice President, Process Development and Manufacturing, will participate in the Cantor Fitzgerald Key Considerations for Gene Therapy Manufacturing and Platforms virtual panel at 10:00 a.m. ET on Wednesday, October 28, 2020.

The panel will focus on the critical components and capabilities to gene therapy manufacturing, including a discussion on AGTCs proprietary manufacturing processes associated with AAV, and key company catalysts expected over the next 12 months. The call will be moderated by Kristen Kluska, Biotechnology Research Analyst of Cantor Fitzgerald.

Presentation Information:Panel: Key Considerations for Gene Therapy Manufacturing and PlatformsDate: Wednesday, October 28, 2020Time: 10:00 a.m. 11:30 a.m. ET

To register for the event, please click here.

About AGTCAGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Companys most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Companys industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS:David Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768 or (646) 871-8485david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:Bill SullivanChief Financial OfficerApplied Genetic Technologies CorporationT: (617) 843-5728bsullivan@agtc.com

Stephen PotterChief Business OfficerApplied Genetic Technologies CorporationT: (617) 413-2754spotter@agtc.com

Read the original post:
AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms - GlobeNewswire

Setting the stage for an extraordinary one-day meeting of the Vaccines and Related Biological Products Advisory Committee this Thursday, the FDA has cleared 2 experts of financial conflicts to help beef up the committee. And regulators went on to specify the safety, efficacy and CMC input theyre looking for on EUAs, before they move on to the full BLA approval process.

All of this has already been spelled out to the developers. But the devil is in the details, and its clear from the first round of posted responses that some of the top players including J&J and Pfizer would like some adjustments and added feedback. And on Thursday, the experts can offer their own thoughts on shaping the first OKs.

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

More:
Bo Cumbo jumps from the top commercial post at Sarepta to the helm of a gene therapy startup with some influential backers, big plans and $107M -...

Blindness is a global problem where a person cannot see anything, including light. Researchers find novel ways like gene therapy to impart vision, and they initially experimented with mice. They claimed to restore vision in totally blind mice with the help of gene therapy.

Opsins are a group of proteins, that is light sensitive through the presence of chromophore retinal found in the photoreceptor cells of the retina. These opsins only covalently bind to vitamin-A based retinaldehyde in both rods and cones. This starts a cascade of signals when the light activates the photoreceptor cells in the retina. This causes pulsations, which propagates by creating an impulse through the optic nerve to the brain.

- Advertisement -

Several disease conditions like macula degeneration, retinitis pigmentosa were causing damage to the photoreceptor cells, which in turn leading to blindness.

Read Also: The water industry can be made more sustainable by a better understanding of biofilms

Scientists said that they can still restore vision even if the photoreceptor cells are impaired. This is by a group of neurons, which we say bipolar cells, can help to evade blindness. When photoreceptor cells failed, other neuronal cells would remain intact.

This is possible when we insert the MCO1 opsin gene to the intact bipolar cells in the retina, which is downstream to the photoreceptors. Hence, the ability to see objects or light enhances.

- Advertisement -

This gene therapy could overcome other treatments such as replacement of opsin, invasive surgery, and all that. Also, this treatment is effective in causing 20/60 vision in patients. Clinical trials are necessary to depict a clear picture of showing how it works when it comes to fast-moving objects, and whether it affects vision quality.

Experiments with mice did not yield any harmful effects upon the administration of genes. If everything goes well, they can successfully implement the treatment, and it will definitely be an alternative to the retinal prosthesis such as retinitis pigmentosa.

Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!

Source: Medical Xpress

- Advertisement -

+ An antiparasitic drug holds well to treat blood cancer+ The peer pressure of a medical dream in India

+ Pakistan reverses TikTok Ban+ Netflix gets experimental: Will give an entire country two days of Netflix for free

See the original post here:
Gene therapy to restore vision in mice - News Landed

According to the report the Zion Market Research Reports Premium Insights of Gene Therapy Market Size-Share Analysis and System Production (2020-2026) | Addressing the Potential Impact of COVID-19 by ZMR. The global Gene Therapy Market report offers an in-depth analysis of the Gene Therapy Market. It presents a succinct outline of theGene Therapy Marketand explains the major key elements of the market. Additionally, the report highlights significant players in the global Gene Therapy Market along with their investment in the market to assess their growth during the estimated time. The foremost market players in the industry are also included in this report for a better understanding of business strategies, growth analysis, sales and revenue and growth factors. The report discusses the most recent expansions while predicting the development of the key players in the near future.

FREE | Request Sample is Available @https://www.zionmarketresearch.com/sample/gene-therapy-market

Major Company Profiles Covered in This Report:

UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics

Our team of experts is consistently working on up-to-date data and information on business processes related to key players who value the market. For future strategies and predictions, we have provided a special section on the covid-19 situation.

The report assesses the global Gene Therapy Market volume in the recent years. Additionally, the report also highlights key controllers and drivers determining the market expansions. It also uncovers the estimate of the market for the predicted time. The report emphasizes the emergent trends related to development possibilities of the global Gene Therapy Market. Moreover, the market report includes the main product category and industry key segments as well as the sub-segments of the global Gene Therapy Market.

Additionally, the total value sequence of the market is also portrayed in the report linked with the analysis of the downstream and upstream constituents of the market. The global Gene Therapy Market is divided based on the category of product and the customer request segments. The market analysis includes the growth of every segment of the global Gene Therapy Market. The data introduced in the report are gathered from varied industry bodies to estimate the growth of the segments in the upcoming time.

Request Free research report Brochure @https://www.zionmarketresearch.com/requestbrochure/gene-therapy-market

The global Gene Therapy Market research report evaluates the market expansion crosswise over major regional segments. It is sorted on the basis of topography such as Europe, Asia Pacific, Latin America, North America, and the Middle East & Africa.

Our free and free sample report accommodates a brief introduction to the research report, summary, list of tables and figures, competitive landscape and geographic segmentation, innovation and future developments based on the research method

Highlights of Gene Therapy Market Research Report:

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/gene-therapy-market

This study will address some of the most critical questions which are listed below:

The Gene Therapy Market is growing at a rapid pace and with the rise in technological innovation, competition and M&A activities in the industry. Further, the research report is segmented on the basis of Application & Other with historical and projected market share and compounded annual growth rate (CAGR). In addition, the research provides key market features, revenue, capacity, capacity, price, growth rate, consumption, production, supply & demand, market share, and CAGR. The report offers a wide-ranging study of imperative market dynamics and their latest trends, coupled with pertinent market segments.

Request coronavirus impact analysis on sectors and market

Request impact analysis on this market @https://www.zionmarketresearch.com/custom/3218?covid19=true

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll Free No.1-855-465-4651

Email:sales@zionmarketresearch.com

Website:www.zionmarketresearch.com

Link:
Premium Insights of Gene Therapy Market Size-Share Analysis and System Production (2020-2026) | Addressing the Potential Impact of COVID-19 by ZMR -...

The latest published an effective statistical data titled as Cardiac Autonomic Neuropathy Treatment Market. It defines about the recent innovations, applications and end users of the market. It covers the different aspects, which are responsible for the growth of the industries. Different domains are considered on the basis of the capital of Cardiac Autonomic Neuropathy Treatment market. The analyst examines different companies on the basis of their productivity to review the current strategies. All leading players across the globe, are profiled with different terms, such as product types, industry outlines, sales and much more.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2817289&source=atm

The study throws light on the recent trends, technologies, methodologies, and tools, which can boost the performance of companies. For further market investment, it gives the depth knowledge of different market segments, which helps to tackle the issues in businesses. It includes effective predictions about the growth factors and restraining factors that can help to enlarge the businesses by finding issues and acquire more outcomes. Leading market players and manufacturers are studied to give a brief idea about competitions. To make well-informed decisions in Cardiac Autonomic Neuropathy Treatment areas, it gives the accurate statistical data.

The analyst also focuses on economic and environmental factors, which impacts on the growth of the businesses. For global analysis, the market is examined by considering the different regions such as North America, Latin America, Japan, China, and India. Leading companies are focusing on spreading their products across the regions. Research and development activities of the various industries are included in the report, to decide the flow of the market.

segment by Type, the product can be split intoSolid OralInjectable

Market segment by Application, split intoHospitalsCardiac CentersAmbulatory Surgical Centers

Based on regional and country-level analysis, the Cardiac Autonomic Neuropathy Treatment market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2817289&source=atm

Competition Analysis

This report examines the ups and downs of the leading key players, which helps to maintain proper balance in the framework. Different global regions, such as Germany, South Africa, Asia Pacific, Japan, and China are analyzed for the study of productivity along with its scope. Moreover, this report marks the factors, which are responsible to increase the patrons at domestic as well as global level.

In the competitive analysis section of the report, leading as well as prominent players of the global Cardiac Autonomic Neuropathy Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyPfizerRoche HoldingNovartisAmgenPrivi PharmaSilverline ChemicalsAnthem BiopharmaPraxis Pharmaceutical

It gives a detailed description of drivers and opportunities in Cardiac Autonomic Neuropathy Treatment market that helps the consumers and potential customers to get a clear vision and take effective decisions. Different analysis models, such as, Cardiac Autonomic Neuropathy Treatment are used to discover the desired data of the target market. In addition to this, it comprises various strategic planning techniques, which promotes the way to define and develop the framework of the industries.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2817289&licType=S&source=atm

The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Cardiac Autonomic Neuropathy Treatment market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

The content of the study subjects, includes a total of 15 chapters:

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Cardiac Autonomic Neuropathy Treatment Market Analysis, Trends, Growth Factor

Chapter 5 Cardiac Autonomic Neuropathy Treatment Market Application and Business with Potential Analysis

Chapter 6 Global Cardiac Autonomic Neuropathy Treatment Market Segment, Type, Application

Chapter 7 Global Cardiac Autonomic Neuropathy Treatment Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Cardiac Autonomic Neuropathy Treatment Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Contact Us:

marketresearchhub

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About marketresearchhub

marketresearchhub is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

More:
Cardiac Autonomic Neuropathy Treatment Market: Expansion Strategies Set to Generate Substantial Revenue in the near Future - Eurowire

Latest added Global Chemotherapy Induced Peripheral Neuropathy Treatment Market research study offers detailed product outlook and elaborates market review till 2025. The market Study is segmented by key regions that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources.

This report studies the Global Chemotherapy Induced Peripheral Neuropathy Treatment market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the Global Chemotherapy Induced Peripheral Neuropathy Treatment market by companies, region, type and end-use industry.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/14077

to Avail deep insights of Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, competition landscape is provided i.e. Revenue Analysis (M $US) by Company (2017-2019), Segment Revenue Market Share (%) by Players (2017-2019) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Competitive Analysis:

The major players are focusing highly on innovation in technologies to improving efficiency level. The industry growth outlook is captured by ensuring ongoing process improvements of players and optimal strategies taken up by companies to fight COVID-19 Situation.

The following players are covered in this report:

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Solasia Pharma K.K.

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/14077

Market Segments: The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market has been divided into type, application, and region.

Breakdown Data by Type

Calcium Channel 2-delta Ligands

Antidepressants

Opioids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by Application

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Based on regional and country-level analysis, the Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

On The basis of region, the Chemotherapy Induced Peripheral Neuropathy Treatment is segmented into countries, with production, consumption, revenue (million USD), and market share and growth rate in these regions, from 2014 to 2025 (forecast), see highlights below

Have Any Query ask to our Expert @ https://beathanreports.com/get-expert-help/14077

What we can offer in the Strategic Opportunities

We analysts identify in broad terms why some companies are gaining or losing share within a given market segment. Every company have its own story and changes in market share are knowingly the most important indicator of management effectiveness & corporate strategies; it is important to identify those who are succeeding in the market and those who are failing, and the cause of the market flux. Key Financial Ratios are also considered to get towards root-cause analysis of each companies such as Return on Assets, ROCE, and Return on Equity etc. From this understanding of the forces driving the market, the analyst team prepares its strategic recommendations. Ultimately, its that market wisdom, beyond the market data and forecasts, which is the most valuable component of market research studies and provides our clientele with the greatest competitive edge with top level quality standards.

How insights and forecasts from the reports could benefit you:

More here:
Chemotherapy Induced Peripheral Neuropathy Treatment Market to Increase Exponentially During 2020 2027 - Eurowire

Many patients think of cancer care as chemotherapy or surgery to remove a tumor or mass. But, there is one important treatment that is often overlooked: rehabilitation.

Breast cancer, in particular, can leave many patients with painful symptoms and side effects that rehabilitation could help ease.

Weve noticed that many patients with breast cancer have greatly benefited from the rehabilitation care we can provide, says Sean Smith, M.D., an associate professor of physical medicine and rehabilitation at Michigan Medicine and medical director of the Cancer Rehabilitation Program at the University of Michigan Rogel Cancer Center.

The Cancer Rehabilitation Program offers patients, with any type of cancer, at any point in treatment, comprehensive rehabilitation services and care.

One of our most robust programs for patients with breast cancer is the lymphedema program, which involves hands-on therapy by specialty-trained occupational therapists, Smith says. But, we also see a lot of patients greatly improve from symptoms such as pain in the shoulder and chest, and stiffness from aromatase inhibitors, or medications that stop the production of estrogen in postmenopausal women.

Smith says many patients with breast cancer often dont realize rehabilitation care is available for them, and that its performed by experts specifically trained to help the patient group.

The expertise for rehabilitating cancer patients at Michigan Medicine is matched by few institutions, he says. Patients coming here can be sure that they will receive a thorough, detailed and individualized approach to their care by people who understand the complicated and difficult medical treatment they have received.

Here, Smith highlights five reasons why rehabilitation care is important for patients with breast cancer.

1. Rehabilitation care helps to treat the physical and mental side effects of cancer.

Smith says the most common reason for rehabilitation care in patients with breast cancer is chest or shoulder issues after surgery and radiation. This can include pain, tightness, numbness and more.

We also diagnose and treat problems related to chemotherapy, including neuropathy or cognitive issues, aromatase inhibitors, such as stiffness, pain and trigger finger, and the disease itself, such as back pain and cognitive issues with metastatic disease, he says.

The team helps with both the physical aspects of rehabilitation, such as a patient needing supportive braces or having a tough time reaching overhead due to tightness from radiation therapy, as well as the cognitive side effects of cancer treatment.

We help patients that have neuropathy from chemotherapy and we provide options for treatment including balance therapy, Smith says. We also help treat chemobrain, or what patients often describe as a mental cloudiness or cognitive impairment from chemotherapy.

2. Cancer rehabilitation care is specialized to the patients specific needs.

The Cancer Rehabilitation Program practices what they call impairment-driven cancer rehabilitation.

Thats a complicated way of saying we treat whatever problem a patient describes, Smith says. For example, if a patient wants to be able to throw a ball with her grandchild, we work on that. Our program is always 100% patient-centered and individualized to their needs.

Smith says the cancer rehabilitation team includes physicians, physical and occupational therapists, psychologists and additional experts, to address whichever needs a patient is experiencing.

The physicians are cancer rehabilitation physicians, which means that they sub-specialize in treating neurologic, musculoskeletal and cognitive problems that patients experience due to cancer treatment, he says. Our therapists often receive additional certifications to be able to best treat cancer-related issues, including lymphedema, radiation fibrosis and more.

3. Rehabilitation care benefits patients at any point along their cancer treatment timeline.

Whether a patient is currently going through breast cancer treatment, or is in remission, the cancer rehabilitation team is ready to help.

We treat patients all along the cancer treatment timeline from those newly diagnosed, to those who have been free of disease for decades, to those with metastatic disease, Smith says. Before we meet a patient, we conduct a thorough review of their cancer treatment history so that we are prepared to make a plan after talking with the patient.

4. Patients dont need a referral to see a rehabilitation specialist.

Making an appointment with a cancer rehabilitation specialist at Michigan Medicine can be done a couple of ways.

Often times, patients are referred by one of their oncology providers to see either a physician, therapist or psychologist, Smith says. Of course we also have patients call for an appointment without a referral, which is great, too.

He notes that once a patient sees one member of the team, they are sometimes referred to another provider if it would help in their overall treatment.

A physician might refer a patient for lymphedema therapy, or a therapist may suggest a referral to a psychologist if the patient is struggling with cognitive issues, Smith says.

5. Adding rehabilitation care to cancer treatment can benefit a patients quality of life.

Patients who are treated for cancer often are assumed to be back to normal when their treatment ends, but Michigan Medicine and the U-M Rogel Cancer Center recognize that is not the case, Smith says. Its not uncommon for patients to be dealing with the after effects of cancer treatment long after treatment ends.

The rehabilitation team of experts can help restore a patients quality of life, no matter what type of cancer they are experiencing. Smith says the goal is always to get the patient back to doing what they enjoy, whether that be spending time with their family, returning to work or keeping up with their hobbies.

He adds, Patients with breast cancer, or any form of cancer, don't have to endure these issues, but they often don't know how to get help or the amount of help that is available to them. They can take the first step by contacting our team, or asking their doctor for a referral. We would love to meet with them and develop a plan to help them recover from cancer-related symptoms.

Learn more about the Cancer Rehabilitation Program and schedule an appointment.

The rest is here:
5 Reasons Rehabilitation Care is Important After Breast Cancer - University of Michigan Health System News

This article was originally published here

Brain Dev. 2020 Oct 19:S0387-7604(20)30272-2. doi: 10.1016/j.braindev.2020.09.009. Online ahead of print.

ABSTRACT

BACKGROUND: Infantile-onset multisystem neurologic, endocrine, and pancreatic disease (IMNEPD) is an extremely rare autosomal recessive disorder with variable expressivity, caused by biallelic mutations in the PTRH2 gene. Core features are global developmental delay or isolated speech delay, intellectual disability, sensorineural hearing loss, ataxia, and pancreatic insufficiency (both exocrine and endocrine). Additional features may include postnatal microcephaly, peripheral neuropathy, facial dysmorphism, and cerebellar atrophy. In literature, there are only a few anecdotal case reports and none of the previous cases presented with diabetic ketoacidosis.

METHODS: We are reporting a 12-year old adolescent girl with mild intellectual disability who presented with fever, pain abdomen for 2 days, and fast breathing for one day.

RESULTS: Her random blood sugar was 472 mg/dl and arterial blood gas revealed high anion gap metabolic acidosis. Urine examination showed ketonuria. On further evaluation, she was found to have demyelinating sensorimotor polyneuropathy and sensorineural hearing loss. Neuroimaging and other ancillary investigations were normal. Whole exome sequencing revealed a novel homozygous single base pair duplication in exon 1 of the PTRH2 gene (c.127dupA, p.Ser43LysfsTer11), confirming the diagnosis of IMNEPD.

CONCLUSIONS: Apart from describing a novel single base pair duplication causing protein truncation in the PTRH2 gene for the first time, our case also expanded the clinical spectrum of IMNEPD, as this is the first case with seemingly pure neurodevelopmental phenotype, who later developed diabetes mellitus, without any exocrine pancreatic abnormality. IMNEPD should be considered in children or adolescents with global developmental delay or intellectual disability when they develop diabetes mellitus.

PMID:33092935 | DOI:10.1016/j.braindev.2020.09.009

Read more here:
Diabetes mellitus in an adolescent girl with intellectual disability caused by novel single base pair duplication in the PTRH2 gene: Expanding the...

LOS ANGELES, United States: QY Research has recently published a research report titled, Global Pharmaceutical and Biotechnology Environmental Monitoring Market Size, Status and Forecast 2020-2026. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Pharmaceutical and Biotechnology Environmental Monitoring market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Pharmaceutical and Biotechnology Environmental Monitoring market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Pharmaceutical and Biotechnology Environmental Monitoring market.

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Pharmaceutical and Biotechnology Environmental Monitoring market.

Key questions answered in the report:

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Pharmaceutical and Biotechnology Environmental Monitoring Revenue1.4 Market by Type1.4.1 Global Pharmaceutical and Biotechnology Environmental Monitoring Market Size Growth Rate by Type: 2020 VS 20261.4.2 Monitoring Equipment1.4.3 Media1.4.4 Software1.4.5 Microbiology Service1.5 Market by Application1.5.1 Global Pharmaceutical and Biotechnology Environmental Monitoring Market Share by Application: 2020 VS 20261.5.2 Pharmaceutical Industrial1.5.3 Biotechnology Industrial1.5.4 Academic Institutions1.5.5 Research Institutions1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Global Pharmaceutical and Biotechnology Environmental Monitoring Market Perspective (2015-2026)2.2 Global Pharmaceutical and Biotechnology Environmental Monitoring Growth Trends by Regions2.2.1 Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Pharmaceutical and Biotechnology Environmental Monitoring Historic Market Share by Regions (2015-2020)2.2.3 Pharmaceutical and Biotechnology Environmental Monitoring Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Pharmaceutical and Biotechnology Environmental Monitoring Market Growth Strategy2.3.6 Primary Interviews with Key Pharmaceutical and Biotechnology Environmental Monitoring Players (Opinion Leaders)

3 Competition Landscape by Key Players3.1 Global Top Pharmaceutical and Biotechnology Environmental Monitoring Players by Market Size3.1.1 Global Top Pharmaceutical and Biotechnology Environmental Monitoring Players by Revenue (2015-2020)3.1.2 Global Pharmaceutical and Biotechnology Environmental Monitoring Revenue Market Share by Players (2015-2020)3.1.3 Global Pharmaceutical and Biotechnology Environmental Monitoring Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Pharmaceutical and Biotechnology Environmental Monitoring Market Concentration Ratio3.2.1 Global Pharmaceutical and Biotechnology Environmental Monitoring Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Pharmaceutical and Biotechnology Environmental Monitoring Revenue in 20193.3 Pharmaceutical and Biotechnology Environmental Monitoring Key Players Head office and Area Served3.4 Key Players Pharmaceutical and Biotechnology Environmental Monitoring Product Solution and Service3.5 Date of Enter into Pharmaceutical and Biotechnology Environmental Monitoring Market3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)4.1 Global Pharmaceutical and Biotechnology Environmental Monitoring Historic Market Size by Type (2015-2020)4.2 Global Pharmaceutical and Biotechnology Environmental Monitoring Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)5.1 Global Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Application (2015-2020)5.2 Global Pharmaceutical and Biotechnology Environmental Monitoring Forecasted Market Size by Application (2021-2026)

6 North America6.1 North America Pharmaceutical and Biotechnology Environmental Monitoring Market Size (2015-2020)6.2 Pharmaceutical and Biotechnology Environmental Monitoring Key Players in North America (2019-2020)6.3 North America Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Type (2015-2020)6.4 North America Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Application (2015-2020)

7 Europe7.1 Europe Pharmaceutical and Biotechnology Environmental Monitoring Market Size (2015-2020)7.2 Pharmaceutical and Biotechnology Environmental Monitoring Key Players in Europe (2019-2020)7.3 Europe Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Type (2015-2020)7.4 Europe Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Application (2015-2020)

8 China8.1 China Pharmaceutical and Biotechnology Environmental Monitoring Market Size (2015-2020)8.2 Pharmaceutical and Biotechnology Environmental Monitoring Key Players in China (2019-2020)8.3 China Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Type (2015-2020)8.4 China Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Application (2015-2020)

9 Japan9.1 Japan Pharmaceutical and Biotechnology Environmental Monitoring Market Size (2015-2020)9.2 Pharmaceutical and Biotechnology Environmental Monitoring Key Players in Japan (2019-2020)9.3 Japan Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Type (2015-2020)9.4 Japan Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Application (2015-2020)

10 Southeast Asia10.1 Southeast Asia Pharmaceutical and Biotechnology Environmental Monitoring Market Size (2015-2020)10.2 Pharmaceutical and Biotechnology Environmental Monitoring Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Type (2015-2020)10.4 Southeast Asia Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Application (2015-2020)

11 India11.1 India Pharmaceutical and Biotechnology Environmental Monitoring Market Size (2015-2020)11.2 Pharmaceutical and Biotechnology Environmental Monitoring Key Players in India (2019-2020)11.3 India Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Type (2015-2020)11.4 India Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Application (2015-2020)

12 Central & South America12.1 Central & South America Pharmaceutical and Biotechnology Environmental Monitoring Market Size (2015-2020)12.2 Pharmaceutical and Biotechnology Environmental Monitoring Key Players in Central & South America (2019-2020)12.3 Central & South America Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Type (2015-2020)12.4 Central & South America Pharmaceutical and Biotechnology Environmental Monitoring Market Size by Application (2015-2020)

13 Key Players Profiles13.1 Danaher Corporation13.1.1 Danaher Corporation Company Details13.1.2 Danaher Corporation Business Overview13.1.3 Danaher Corporation Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.1.4 Danaher Corporation Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020))13.1.5 Danaher Corporation Recent Development13.2 Thermo Fisher Scientific13.2.1 Thermo Fisher Scientific Company Details13.2.2 Thermo Fisher Scientific Business Overview13.2.3 Thermo Fisher Scientific Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.2.4 Thermo Fisher Scientific Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.2.5 Thermo Fisher Scientific Recent Development13.3 Merck13.3.1 Merck Company Details13.3.2 Merck Business Overview13.3.3 Merck Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.3.4 Merck Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.3.5 Merck Recent Development13.4 Eurofins Sinensis13.4.1 Eurofins Sinensis Company Details13.4.2 Eurofins Sinensis Business Overview13.4.3 Eurofins Sinensis Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.4.4 Eurofins Sinensis Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.4.5 Eurofins Sinensis Recent Development13.5 Lonza13.5.1 Lonza Company Details13.5.2 Lonza Business Overview13.5.3 Lonza Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.5.4 Lonza Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.5.5 Lonza Recent Development13.6 Biomerieux13.6.1 Biomerieux Company Details13.6.2 Biomerieux Business Overview13.6.3 Biomerieux Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.6.4 Biomerieux Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.6.5 Biomerieux Recent Development13.7 VAI13.7.1 VAI Company Details13.7.2 VAI Business Overview13.7.3 VAI Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.7.4 VAI Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.7.5 VAI Recent Development13.8 Cosasco13.8.1 Cosasco Company Details13.8.2 Cosasco Business Overview13.8.3 Cosasco Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.8.4 Cosasco Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.8.5 Cosasco Recent Development13.9 RMONI13.9.1 RMONI Company Details13.9.2 RMONI Business Overview13.9.3 RMONI Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.9.4 RMONI Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.9.5 RMONI Recent Development13.10 Amphenol Advanced Sensors13.10.1 Amphenol Advanced Sensors Company Details13.10.2 Amphenol Advanced Sensors Business Overview13.10.3 Amphenol Advanced Sensors Pharmaceutical and Biotechnology Environmental Monitoring Introduction13.10.4 Amphenol Advanced Sensors Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)13.10.5 Amphenol Advanced Sensors Recent Development13.11 Vaisala10.11.1 Vaisala Company Details10.11.2 Vaisala Business Overview10.11.3 Vaisala Pharmaceutical and Biotechnology Environmental Monitoring Introduction10.11.4 Vaisala Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)10.11.5 Vaisala Recent Development13.12 Particle Measurement Systems10.12.1 Particle Measurement Systems Company Details10.12.2 Particle Measurement Systems Business Overview10.12.3 Particle Measurement Systems Pharmaceutical and Biotechnology Environmental Monitoring Introduction10.12.4 Particle Measurement Systems Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)10.12.5 Particle Measurement Systems Recent Development13.13 Hanwell10.13.1 Hanwell Company Details10.13.2 Hanwell Business Overview10.13.3 Hanwell Pharmaceutical and Biotechnology Environmental Monitoring Introduction10.13.4 Hanwell Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)10.13.5 Hanwell Recent Development13.14 Novatek10.14.1 Novatek Company Details10.14.2 Novatek Business Overview10.14.3 Novatek Pharmaceutical and Biotechnology Environmental Monitoring Introduction10.14.4 Novatek Revenue in Pharmaceutical and Biotechnology Environmental Monitoring Business (2015-2020)10.14.5 Novatek Recent Development

14 Analysts Viewpoints/Conclusions

15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Pharmaceutical and Biotechnology Environmental Monitoring Market Trend, Industry Analysis, COVID-19 Impact, Growth Rate and Future Forecast 2020-2026...

Bioscience research is undergoing a wave of automation and digitization, turning a manual, laborious practice into a true industry.

Why it matters: Biotechnology promises to revolutionize everything from medicine to energy, but for that to happen, the field needs to move out of the traditional lab and into something resembling a foundry. The growth of robotics and cloud-based remote research can help make that happen.

What's happening: In a report published last week, the design and engineering firm Arup made the case that the future of scientific labs will increasingly be automated and digitized, allowing researchers to carry out experiments remotely and scale up their work faster.

How it works: That means labs where experiments can be automated think robot arms moving vials en masse, rather than overworked graduate students pipetting by hand.

Of note: Benchling, which helps life science researchers remotely track and share data, has seen a 35% increase in platform use from customers working on COVID-19.

Zoom in: Speed and industrialization in the lab are particularly vital for developing a COVID-19 vaccine in record time.

Context: Ginkgo Bioworks, which is now valued at more than $4 billion, represents the cutting edge of biotech industrialization.

What's next: On Tuesday, the Department of Defense announced it would award $87.5 million which will be matched by more than $180 million in non-federal funding to establish a manufacturing innovation institute called BioMADE at the University of Minnesota.

The bottom line: If the 21st century really is going to be the "age of biology," as some experts have predicted, the field needs to undergo its own version of the Industrial Revolution.

See the article here:
Biology is having its industrial revolution - Axios

The 55 rating InvestorsObserver gives to Adaptimmune Therapeutics PLC - ADR (ADAP) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 64 percent of stocks in the Biotechnology industry, ADAPs 55 overall rating means the stock scores better than 55 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Adaptimmune Therapeutics PLC - ADR (ADAP) stock has risen 12.79% while the S&P 500 is down -0.07% as of 11:50 AM on Friday, Oct 23. ADAP has gained $0.55 from the previous closing price of $4.30 on volume of 879,311 shares. Over the past year the S&P 500 is up 14.64% while ADAP has gained 444.94%. ADAP lost -$1.10 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Adaptimmune Therapeutics PLC - ADR (ADAP) Stock.

See the rest here:
Is Adaptimmune Therapeutics PLC - ADR (ADAP) a Winner in the Biotechnology Industry? - InvestorsObserver

Cardiff Oncology Inc (CRDF) is around the top of the Biotechnology industry according to InvestorsObserver. CRDF received an overall rating of 89, which means that it scores higher than 89 percent of all stocks. Cardiff Oncology Inc also achieved a score of 99 in the Biotechnology industry, putting it above 99 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Cardiff Oncology Inc (CRDF) stock is trading at $13.30 as of 11:34 AM on Thursday, Oct 22, a gain of $1.28, or 10.65% from the previous closing price of $12.02. The stock has traded between $12.50 and $13.41 so far today. Volume today is below average. So far 427,977 shares have traded compared to average volume of 3,743,546 shares.

Click Here to get the full Stock Score Report on Cardiff Oncology Inc (CRDF) Stock.

See the original post here:
Is Cardiff Oncology Inc (CRDF) a Winner in the Biotechnology Industry? - InvestorsObserver

Pharmaceutical & Biotechnology Environmental Monitoring Market 2020: Latest Analysis

Chicago, United States:- Global Pharmaceutical & Biotechnology Environmental Monitoring Market reports offers important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends.

Each segment of the global Pharmaceutical & Biotechnology Environmental Monitoring market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Pharmaceutical & Biotechnology Environmental Monitoring market through leading segments. The regional study of the global Pharmaceutical & Biotechnology Environmental Monitoring market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Pharmaceutical & Biotechnology Environmental Monitoring market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Pharmaceutical & Biotechnology Environmental Monitoring Market report offers a detailed Outlook and future prospects of the Industry. The Pharmaceutical & Biotechnology Environmental Monitoring Market report includes various topics like market size & share, Product types, applications, key market drivers & restraints, challenges, growth opportunities, key players, competitive landscape.

Top Players of Pharmaceutical & Biotechnology Environmental Monitoring Market are Studied: Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins Sinensis, Lonza, Biomerieux, VAI, Cosasco, RMONI, Amphenol Advanced Sensors, Vaisala

Download Free Sample PDF (including full TOC, Tables, and Figures) of Pharmaceutical & Biotechnology Environmental Monitoring Market Research 2020-2026:- @

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Pharmaceutical & Biotechnology Environmental Monitoring market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Pharmaceutical & Biotechnology Environmental Monitoring market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

NOTE:Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Pharmaceutical & Biotechnology Environmental Monitoring Market which would mention How the Covid-19 is Affecting the Pharmaceutical & Biotechnology Environmental Monitoring Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Pharmaceutical & Biotechnology Environmental Monitoring Players to Combat Covid-19 Impact.

Environmental monitoring during pharmaceutical and biopharmaceutical production is crucial for ensuring the safety of formulated drug products. While requirements for the control of both viable (living microorganisms) and non-viable particles (e.g. dust, hair, etc.) and other contaminants (i.e. trace metals, volatiles, etc.) for aseptic manufacturing operations are more extensive than those for non-sterile processes, the quantity of samples that must be analyzed and the amount of data generated can be daunting regardless of the final drug form, particularly for global companies with multiple production facilities.

The report forecast global Pharmaceutical & Biotechnology Environmental Monitoring market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation.The report offers detailed coverage of Pharmaceutical & Biotechnology Environmental Monitoring industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Pharmaceutical & Biotechnology Environmental Monitoring by geography. The report splits the market size, by volume and value, on the basis of application type and geography.First, this report covers the present status and the future prospects of the global Pharmaceutical & Biotechnology Environmental Monitoring market for 2015-2024.And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].At the same time, we classify Pharmaceutical & Biotechnology Environmental Monitoring according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.Finally, the report provides detailed profile and data information analysis of leading Pharmaceutical & Biotechnology Environmental Monitoring company.

Our exploration specialists acutely ascertain the significant aspects of the global Pharmaceutical & Biotechnology Environmental Monitoring market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Pharmaceutical & Biotechnology Environmental Monitoring market situation. In this Pharmaceutical & Biotechnology Environmental Monitoring report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Pharmaceutical & Biotechnology Environmental Monitoring report comprises of primary and secondary data which is exemplified in the form of pie outlines, Pharmaceutical & Biotechnology Environmental Monitoring tables, analytical figures, and reference diagrams. The Pharmaceutical & Biotechnology Environmental Monitoring report is presented in an efficient way that involves basic dialect, basic Pharmaceutical & Biotechnology Environmental Monitoring outline, agreements, and certain facts as per solace and comprehension.

Segmentation by Application: Pharmaceutical IndustryBiotechnology IndustryAcademic & Research Institutes

Segmentation by Type: Monitoring EquipmentMediaSoftwareMicrobiology Services

The Essential Content Covered in the GlobalPharmaceutical & Biotechnology Environmental Monitoring Market Report:

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Regional Coverage: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Some Main Reasons For Purchasing This Report:

Readers of this report will receive in-depth knowledge about the market.

Updated statistics offered on the global Pharmaceutical & Biotechnology Environmental Monitoring market report.

This report provides an insight into the market that will help you boost your companys business and sales activities.

It will help you to find prospective partners and suppliers.

It will assist and strengthen your companys decision-making processes.

Get Full Customize report or for any Special Discount [emailprotected] @ https://www.reporthive.com/request_customization/2501701

Table of Contents

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the global Pharmaceutical & Biotechnology Environmental Monitoring market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the global Pharmaceutical & Biotechnology Environmental Monitoring market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations and trends, expansions, merger and acquisition deals, and other subjects. It also shows how different companies are progressing in the global Pharmaceutical & Biotechnology Environmental Monitoring market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the global Pharmaceutical & Biotechnology Environmental Monitoring market. It assesses each and every player studied in the report on the basis of main business, gross margin, revenue, sales, price, competitors, manufacturing base, product specification, product application, and product category.

Market Status and Outlook by Region: The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets researched about in the report are examined based on price, gross margin, revenue, production, and sales. Here, the size and CAGR of the regional markets are also provided.

Market by Product: This section carefully analyzes all product segments of the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Market by Application: Here, various application segments of the global Pharmaceutical & Biotechnology Environmental Monitoring market are taken into account for research study.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the global Pharmaceutical & Biotechnology Environmental Monitoring market. The forecasts are also provided taking into consideration product, application, and regional segments of the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Upstream Raw Materials: This section includes industrial chain analysis, manufacturing cost structure analysis, and key raw materials analysis of the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Marketing Strategy Analysis, Distributors: Here, the research study digs deep into behavior and other factors of downstream customers, distributors, development trends of marketing channels, and marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Appendix: This is the last section of the report that focuses on data sources, viz. primary and secondary sources, market breakdown and data triangulation, market size estimation, research programs and design, research approach and methodology, and the publishers disclaimer.

Get Free Sample Copy of this report: https://www.reporthive.com/request_sample/2501701

Why Go For Report Hive Research?Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Pharmaceutical & Biotechnology Environmental Monitoring Market Forecast, Pharmaceutical & Biotechnology Environmental Monitoring Market Trends, Pharmaceutical & Biotechnology Environmental Monitoring Market Research, Pharmaceutical & Biotechnology Environmental Monitoring, Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis, Pharmaceutical & Biotechnology Environmental Monitoring application, Pharmaceutical & Biotechnology Environmental Monitoring Market CAGR Competitive Landscape, Pharmaceutical & Biotechnology Environmental Monitoring Market Growth

Get in Touch with Us :

Report Hive Research

Website: https://www.reporthive.com

Email: [emailprotected]

Speak to Research Analyst: +1-312-604-7084

Read more:
Covid-19 Impact On Pharmaceutical & Biotechnology Environmental Monitoring Market : Growth, Segmentation Analysis By Application And Regions To...

DUBLIN, Oct. 20, 2020 The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report has been added to ResearchAndMarkets.coms offering.

This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2014.

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.

Key benefits

Available deals and contracts are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in joint venture partnerships2.1. Introduction2.2. Definition of joint venture deals2.3. Success factors for joint venture partnerships2.4. When joint venture partnerships can be useful2.5. Attributes of joint venture partnerships2.6. Aligning partners to make the joint venture work2.7. Trends in joint venture partnerships since 20142.7.1. Joint venture dealmaking by year, 2014 to 20202.7.2. Joint venture dealmaking by stage of development 2014 to 20202.7.3. Joint venture dealmaking by industry sector 2014 to 20202.7.4. Joint venture dealmaking by therapy area, 2014 to 20202.7.5. Joint venture dealmaking by technology type, 2014 to 20202.7.6. Joint venture dealmaking by most active company, 2014 to 20202.8. The future of joint venture partnerships

Chapter 3 Overview of joint venture deal structure3.1. Introduction3.2. Joint venture agreement structure3.3. Example joint venture agreements3.3.1. Case study 1: Agila Specialties Pfenex3.3.2. Case study 2: Dance Biopharm Harmony Asset

Chapter 4 Leading joint venture deals4.1. Introduction4.2. Top joint venture deals by value

Chapter 5 Top 25 most active active joint venture dealmakers5.1. Introduction5.2. Top 25 most active joint venture dealmakers

Chapter 6 Joint venture deals including contracts directory6.1. Introduction6.2. Joint venture deals with contracts 2014 to 2020

AppendicesAppendix 1 Joint venture dealmaking by companies A-ZAppendix 2 Joint venture dealmaking by industry sectorAppendix 3 Joint venture dealmaking by stage of developmentAppendix 4 Joint venture dealmaking by therapy areaAppendix 5 Joint venture dealmaking by technology typeAppendix 6 Joint venture referencesAppendix 7 ResourcesAppendix 8 Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/b8myyj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Excerpt from:
Latest Joint Venture Agreements Announced in the Pharmaceutical, Biotechnology and Diagnostic, 2020 - Virtual-Strategy Magazine

Nantkwest Inc (NK) is near the top in its industry group according to InvestorsObserver. NK gets an overall rating of 57. That means it scores higher than 57 percent of stocks. Nantkwest Inc gets a 68 rank in the Biotechnology industry. Biotechnology is number 31 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Nantkwest Inc (NK) stock is trading at $8.10 as of 9:44 AM on Friday, Oct 23, a rise of $0.07, or 0.81% from the previous closing price of $8.04. The stock has traded between $8.08 and $8.44 so far today. Volume today is below average. So far 12,476 shares have traded compared to average volume of 1,109,785 shares.

Click Here to get the full Stock Score Report on Nantkwest Inc (NK) Stock.

The rest is here:
Is Nantkwest Inc (NK) the Top Pick in the Biotechnology Industry? - InvestorsObserver

The 56 rating InvestorsObserver gives to Adaptimmune Therapeutics PLC - ADR (ADAP) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 66 percent of stocks in the Biotechnology industry, ADAPs 56 overall rating means the stock scores better than 56 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 56 would rank higher than 56 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Adaptimmune Therapeutics PLC - ADR (ADAP) stock is down -2.65% while the S&P 500 is higher by 0.14% as of 11:42 AM on Thursday, Oct 22. ADAP has fallen -$0.12 from the previous closing price of $4.53 on volume of 1,246,466 shares. Over the past year the S&P 500 has risen 14.50% while ADAP is higher by 345.45%. ADAP lost -$1.10 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Adaptimmune Therapeutics PLC - ADR (ADAP) Stock.

More:
Is Adaptimmune Therapeutics PLC - ADR (ADAP) The Right Choice in Biotechnology? - InvestorsObserver

Aileron Therapeutics Inc (ALRN) is around the top of the Biotechnology industry according to InvestorsObserver. ALRN received an overall rating of 94, which means that it scores higher than 94 percent of all stocks. Aileron Therapeutics Inc also achieved a score of 100 in the Biotechnology industry, putting it above 100 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 94 would rank higher than 94 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aileron Therapeutics Inc (ALRN) stock is trading at $2.09 as of 10:17 AM on Thursday, Oct 22, a rise of $0.06, or 3.21% from the previous closing price of $2.03. The stock has traded between $2.06 and $2.21 so far today. Volume today is low. So far 240,889 shares have traded compared to average volume of 906,744 shares.

Click Here to get the full Stock Score Report on Aileron Therapeutics Inc (ALRN) Stock.

More:
Is Aileron Therapeutics Inc (ALRN) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The proposed Pre-Loaded Intraocular Lens Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed analysis of market drivers, restraints, technological advancements & competitive landscape along with various micro & macro factors influencing the market dynamics.

The Pre-Loaded Intraocular Lens Market sample report includes an exclusive analysis of COVID-19 pandemic on the market space under scrutiny. The sample represents the format of the overall study which is designed to provide clarity on the structure of the report and some data points demonstrated in an attempt to provide insights into the study quality.

Furthermore, the Pre-Loaded Intraocular Lens Market full research study is designed on account of the fact that each segment is individually assessed and then collated to form the whole market, the study can be tailor-made to fit your exact requirements.

Request Sample Pages of this research study at https://www.theinsightpartners.com/sample/TIPRE00015245/

The structure of the Pre-Loaded Intraocular Lens Market report can be categorized into following sections:

The Prominent/Emerging Players in the Pre-Loaded Intraocular Lens Market Research include:

The Pre-Loaded Intraocular Lens Market Company Profiles are individually represented for all major participants and indices such as Financial Performance, Strategic Initiatives, Product Portfolio & Company Overview.

Company Overview:

Company overview provides the information about location of the company where it is headquartered along with the established year, employee strength as of 2017, regions where the company is operating and the key business areas.

Financial Performance:

Overall company/segment revenue for the year 2019, 2018, and 2017 is provided in the sub title Financial Performance (public listed companies) along with the analysis and explanation of the increase or decrease in the same due to factors such as mergers & acquisition, profit or loss in any strategic business unit (SBUs) and others.

Product Benchmarking:

Product benchmarking comprises the comprehensive list of products pertaining to the respective market along with the application and key features.

Strategic Initiatives:

Insights pertaining to the new product launch, strategic collaboration, mergers and acquisition, regulatory approval, and other developments by the company in market are covered under strategic initiatives section.

Order a copy of this research study at https://www.theinsightpartners.com/buy/TIPRE00015245/

The Pre-Loaded Intraocular Lens Market research study is designed keeping in focus all the major countries. Although, all these countries & their market trends were accounted for while composing it, detailed sections are available for only the spearheads. In case if you would be interested in specific countries which are not covered in the current scope, kindly share the list & we can customize the study based on the geographical scope defined by you.

ABOUT US:

The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Our research model is very simple. We believe in client servicing and delivering best quality to our customers. Through our research content, we are making sure that our customers get value of their money along with better quality data and analysis.

Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis etc. We provide detailed break-up of segmentation in terms of geography, technology, product and services etc.; which helps our clients to get a deeper analysis on various research topics.About Us:

Contact US:

If you have any queries about this report or would like further information, please contact us:

North America: +1 646 491 9876

Asia-Pacific: +91 20 6727 8686

Email: [emailprotected]

View original post here:
Stem Cells in Regenerative Medicine: The Next Frontier in Biotechnology - The Think Curiouser

There are a total 1,221 seats available in 62 courses which will be offered to the students who qualify GAT B 2020

The GAT B 2020 result has been declared by the Regional Centre for Biotechnology on its website - rcb.res.in. Candidates who have appeared for Graduate Aptitude Test - Biotechnology (GAT B) 2020 on 3 October can check their rank and scorecard by entering their application sequence number and date of birth.

The GAT B 2020 result will mention details including the name, roll number of the student, marks secured, rank obtained and qualifying status of the candidate.

Those who qualify the entrance exam will get admission in the participating institutes based on the rankings.

A report by Careers 360 said each participating institute releases its GAT B cut off based on different categories of students. There are a total of 1,221 seats available in 24 participating colleges for 62 courses.

Steps to check GAT B 2020 results:

Step 1: Log on to the official website of Regional Centre for Biotechnology - rcb.res.in.Step 2: On the homepage, under Announcement tab, tap on the link that says, 'GAT-B 2020 Rank Card Live'Step 3: You will be directed to a new page where you have to enter your application sequence number and date of birth in DD/MM/YYYY format.Step 4: Press the Login buttonStep 5: Your GAT B 2020 result mentioning your score and qualifying status will be displayed on screenStep 6: Check all the details before saving your GAT B 2020 score card and take a print out

Here is the direct link to check and download GAT B 2020 result: https://cdn.tcsion.com/EForms/configuredHtml/2880/67816/login.html

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

Read more:
GAT B 2020 eaxm: Results of Graduate Aptitude Test in Biotechnology released at rcb.res.in - Firstpost

LOS ANGELES, United States: QY Research has recently published a research report titled, Global Longevity and Anti-senescence Therapy Market Size, Status and Forecast 2020-2026. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Longevity and Anti-senescence Therapy market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Longevity and Anti-senescence Therapy market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Longevity and Anti-senescence Therapy market.

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Longevity and Anti-senescence Therapy market.

Key questions answered in the report:

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Longevity and Anti-senescence Therapy Revenue1.4 Market by Type1.4.1 Global Longevity and Anti-senescence Therapy Market Size Growth Rate by Type: 2020 VS 20261.4.2 Hemolytic Drug Therapy1.4.3 Gene Therapy1.4.4 Immunotherapy1.4.5 Other Stem Cell Therapies1.5 Market by Application1.5.1 Global Longevity and Anti-senescence Therapy Market Share by Application: 2020 VS 20261.5.2 Hospital1.5.3 Medical Service Institution1.5.4 Drug and Device Sales1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Global Longevity and Anti-senescence Therapy Market Perspective (2015-2026)2.2 Global Longevity and Anti-senescence Therapy Growth Trends by Regions2.2.1 Longevity and Anti-senescence Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Longevity and Anti-senescence Therapy Historic Market Share by Regions (2015-2020)2.2.3 Longevity and Anti-senescence Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Longevity and Anti-senescence Therapy Market Growth Strategy2.3.6 Primary Interviews with Key Longevity and Anti-senescence Therapy Players (Opinion Leaders)

3 Competition Landscape by Key Players3.1 Global Top Longevity and Anti-senescence Therapy Players by Market Size3.1.1 Global Top Longevity and Anti-senescence Therapy Players by Revenue (2015-2020)3.1.2 Global Longevity and Anti-senescence Therapy Revenue Market Share by Players (2015-2020)3.1.3 Global Longevity and Anti-senescence Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Longevity and Anti-senescence Therapy Market Concentration Ratio3.2.1 Global Longevity and Anti-senescence Therapy Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Longevity and Anti-senescence Therapy Revenue in 20193.3 Longevity and Anti-senescence Therapy Key Players Head office and Area Served3.4 Key Players Longevity and Anti-senescence Therapy Product Solution and Service3.5 Date of Enter into Longevity and Anti-senescence Therapy Market3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)4.1 Global Longevity and Anti-senescence Therapy Historic Market Size by Type (2015-2020)4.2 Global Longevity and Anti-senescence Therapy Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)5.1 Global Longevity and Anti-senescence Therapy Market Size by Application (2015-2020)5.2 Global Longevity and Anti-senescence Therapy Forecasted Market Size by Application (2021-2026)

6 North America6.1 North America Longevity and Anti-senescence Therapy Market Size (2015-2020)6.2 Longevity and Anti-senescence Therapy Key Players in North America (2019-2020)6.3 North America Longevity and Anti-senescence Therapy Market Size by Type (2015-2020)6.4 North America Longevity and Anti-senescence Therapy Market Size by Application (2015-2020)

7 Europe7.1 Europe Longevity and Anti-senescence Therapy Market Size (2015-2020)7.2 Longevity and Anti-senescence Therapy Key Players in Europe (2019-2020)7.3 Europe Longevity and Anti-senescence Therapy Market Size by Type (2015-2020)7.4 Europe Longevity and Anti-senescence Therapy Market Size by Application (2015-2020)

8 China8.1 China Longevity and Anti-senescence Therapy Market Size (2015-2020)8.2 Longevity and Anti-senescence Therapy Key Players in China (2019-2020)8.3 China Longevity and Anti-senescence Therapy Market Size by Type (2015-2020)8.4 China Longevity and Anti-senescence Therapy Market Size by Application (2015-2020)

9 Japan9.1 Japan Longevity and Anti-senescence Therapy Market Size (2015-2020)9.2 Longevity and Anti-senescence Therapy Key Players in Japan (2019-2020)9.3 Japan Longevity and Anti-senescence Therapy Market Size by Type (2015-2020)9.4 Japan Longevity and Anti-senescence Therapy Market Size by Application (2015-2020)

10 Southeast Asia10.1 Southeast Asia Longevity and Anti-senescence Therapy Market Size (2015-2020)10.2 Longevity and Anti-senescence Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Longevity and Anti-senescence Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Longevity and Anti-senescence Therapy Market Size by Application (2015-2020)

11 India11.1 India Longevity and Anti-senescence Therapy Market Size (2015-2020)11.2 Longevity and Anti-senescence Therapy Key Players in India (2019-2020)11.3 India Longevity and Anti-senescence Therapy Market Size by Type (2015-2020)11.4 India Longevity and Anti-senescence Therapy Market Size by Application (2015-2020)

12 Central & South America12.1 Central & South America Longevity and Anti-senescence Therapy Market Size (2015-2020)12.2 Longevity and Anti-senescence Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Longevity and Anti-senescence Therapy Market Size by Type (2015-2020)12.4 Central & South America Longevity and Anti-senescence Therapy Market Size by Application (2015-2020)

13 Key Players Profiles13.1 CohBar13.1.1 CohBar Company Details13.1.2 CohBar Business Overview13.1.3 CohBar Longevity and Anti-senescence Therapy Introduction13.1.4 CohBar Revenue in Longevity and Anti-senescence Therapy Business (2015-2020))13.1.5 CohBar Recent Development13.2 TA Sciences13.2.1 TA Sciences Company Details13.2.2 TA Sciences Business Overview13.2.3 TA Sciences Longevity and Anti-senescence Therapy Introduction13.2.4 TA Sciences Revenue in Longevity and Anti-senescence Therapy Business (2015-2020)13.2.5 TA Sciences Recent Development13.3 Unity Biotechnology13.3.1 Unity Biotechnology Company Details13.3.2 Unity Biotechnology Business Overview13.3.3 Unity Biotechnology Longevity and Anti-senescence Therapy Introduction13.3.4 Unity Biotechnology Revenue in Longevity and Anti-senescence Therapy Business (2015-2020)13.3.5 Unity Biotechnology Recent Development13.4 AgeX TherapeuticsInc13.4.1 AgeX TherapeuticsInc Company Details13.4.2 AgeX TherapeuticsInc Business Overview13.4.3 AgeX TherapeuticsInc Longevity and Anti-senescence Therapy Introduction13.4.4 AgeX TherapeuticsInc Revenue in Longevity and Anti-senescence Therapy Business (2015-2020)13.4.5 AgeX TherapeuticsInc Recent Development13.5 PowerVision Inc.13.5.1 PowerVision Inc. Company Details13.5.2 PowerVision Inc. Business Overview13.5.3 PowerVision Inc. Longevity and Anti-senescence Therapy Introduction13.5.4 PowerVision Inc. Revenue in Longevity and Anti-senescence Therapy Business (2015-2020)13.5.5 PowerVision Inc. Recent Development

14 Analysts Viewpoints/Conclusions

15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Here is the original post:
Longevity and Anti-senescence Therapy Market Trend, Industry Analysis, COVID-19 Impact, Growth Rate and Future Forecast 2020-2026 | Top Players:...